PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Arrhythmogenic right ventricular cardiomyopathy

Drugs in development · updated 30 October 2026

Arrhythmogenic right ventricular cardiomyopathy: drugs in development

As of 30 October 2026 there are 5 active clinical trials (recruiting or ongoing, phases I–III) on 5 drugs for arrhythmogenic right ventricular cardiomyopathy. 4 are experimental, that is not yet approved in the United States.

5Active trials
4Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
LX2020I–II1NCT06109181
TideglusibII1NCT06174220
RP-A601I1NCT05885412
TN-401I1NCT06228924

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
SpironolactoneCarospir®, Aldactone®II1NCT03593317

Sorted by most advanced phase and number of active trials.

All 5 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D019571 “Arrhythmogenic Right Ventricular Dysplasia”.

ItalianoFrançaisDeutsch